AbbVie

ABBV · NYSE · USD

$262.82+1.11%+$2.89

Close · October 2, 2026

At a glance

Revenue growth: +8.57%; 2025 vs 2024
Net income growth: −1.22%; 2025 vs 2024
Net margin: 6.9%; 2024: 7.6%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total revenue	16,990	15,002	16,618	15,776	15,423	13,343	15,102	14,460	14,462	12,310	14,301	13,927
Cost of revenue	4,291	4,218	4,552	4,457	4,346	4,002	4,217	4,207	4,202	4,063	4,181	4,365
Gross profit	12,699	10,784	12,066	11,319	11,077	9,341	10,885	10,253	10,260	8,247	10,120	9,562
Selling, general and administrative	3,553	3,488	3,819	3,428	3,183	3,214	3,686	4,042	3,314	3,057	3,555	3,267
Research and development	2,344	2,472	2,579	2,291	2,131	2,067	2,298	2,072	1,948	1,813	1,922	1,722
Operating income	6,802	4,824	5,668	5,600	5,787	4,060	4,908	4,139	4,998	3,377	4,474	4,573
EBIT	6,802	4,824	5,668	5,600	5,787	4,060	4,908	4,139	4,998	3,377	4,474	4,573
EBITDA	8,685	6,760	7,655	7,663	7,837	6,099	7,010	6,218	7,129	5,451	6,550	6,808
Interest expense	746	717	714	739	740	700	702	720	726	660	564	555
Pre-tax income	4,278	1,039	2,668	714	1,554	1,661	-2,269	2,084	2,146	1,755	1,212	1,953
Income tax	662	342	853	526	613	372	-2,246	520	773	383	388	172
Net income	3,613	695	1,816	186	938	1,286	-22.0	1,561	1,370	1,369	822	1,778
Net income to common shareholders	3,601	687	1,806	176	928	1,276	-32.0	1,551	1,360	1,359	811	1,767
Basic EPS	2.04	0.39	1.02	0.10	0.52	0.72	-0.02	0.88	0.77	0.77	0.46	1.00
Diluted EPS	2.03	0.39	1.02	0.10	0.52	0.72	-0.02	0.88	0.77	0.77	0.46	1.00
Average shares (basic)	1,769	1,769	1,774	1,769	1,768	1,768	1,769	1,769	1,768	1,769	1,772	1,767
Average shares (diluted)	1,771	1,775	1,774	1,772	1,771	1,772	1,769	1,772	1,771	1,773	1,772	1,771
Dividend per share	1.73	1.73	1.73	1.64	1.64	1.64	1.64	1.55	1.55	1.55	1.55	1.48